<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796183</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1</org_study_id>
    <nct_id>NCT02796183</nct_id>
  </id_info>
  <brief_title>The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema</brief_title>
  <official_title>The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ondokuz MayÄ±s University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neon Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of subconjunctivally injected bevacizumab in patients with&#xD;
      diffuse diabetic macular edema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic&#xD;
      macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was&#xD;
      injected into subconjunctival space of the eyes with diabetic macular edema. The measurements&#xD;
      of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th&#xD;
      day after injections. The macular thickness measurements before and after injection were&#xD;
      compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central Macular Thickness</measure>
    <time_frame>one year (between May 2015 and May 2016)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Diabetic macular edema</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bevacizumab (Altuzan) was injected subconjunctival space of the patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subconjunctival bevacizumab (Altuzan)</intervention_name>
    <description>Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.</description>
    <arm_group_label>Diabetic macular edema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having diffuse diabetic macular edema persisted at least 1 month&#xD;
&#xD;
          -  No intravitreal injection in last 3 months.&#xD;
&#xD;
          -  No retinal laser photocoagulation in last 6 months&#xD;
&#xD;
          -  Not have any other macular disease causing macular edema&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having ischemic macula&#xD;
&#xD;
          -  Intravitreal injection in last 3 months.&#xD;
&#xD;
          -  Retinal laser photocoagulation in last 6 months&#xD;
&#xD;
          -  Have any other macular disease causing macular edema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neon Hospital</investigator_affiliation>
    <investigator_full_name>Volkan YETER</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

